A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: Bortezomib
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Melphalan
DRUG: Prednisone
DRUG: Carfilzomib

Sponsor

Janssen Research & Development, LLC